|
WO2021072137A1
|
|
Heparin-insensitive assay for factor xla
|
|
WO2021050718A1
|
|
Methods of treatment related to complexes of von willebrand factor and complement c1q
|
|
WO2020264411A1
|
|
Adeno-associated virus purification methods
|
|
WO2020257586A2
|
|
Method of treatment with viral-based gene therapy
|
|
WO2020247746A1
|
|
Use of recombinant adamts13 for treating sickle cell disease
|
|
WO2020160460A1
|
|
Methods of prophylactic treatment using recombinant vwf (rvwf)
|
|
US2020246437A1
|
|
Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression
|
|
TW202039546A
|
|
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
CA3112883A1
|
|
Aav triple-plasmid system
|
|
CA3106590A1
|
|
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
AU2019299964A1
|
|
AAV compositions
|
|
WO2020014447A1
|
|
Female-female adapter
|
|
CA3094644A1
|
|
Separation of vwf and vwf propeptide by chromatographic methods
|
|
WO2019011900A1
|
|
Method for incubating liquids and inactivating viruses
|
|
EP3648787A1
|
|
Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
|
|
CN111436193A
|
|
Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
|
|
WO2018234543A1
|
|
Purification of factor viii subspecies
|
|
KR20200010443A
|
|
Viral vector encoding recombinant FIX variant with increased expression for hemophilia B gene therapy
|
|
KR20190122245A
|
|
How to determine the potency of adeno-associated virus preparations
|
|
CN110300591A
|
|
Adeno-associated virus preparation
|
